Af­ter huge mega-round, CStone poach­es Gold­man's Richard Yeh as CFO; Both Hoop­er and Harp­er ex­it Am­gen's re­volv­ing door

→ Weeks af­ter clos­ing its star-stud­ded $260 mil­lion Se­ries B round, CStone Phar­ma­ceu­ti­cals has poached Gold­man Sachs di­rec­tor Richard Yeh to man­age all of that mon­ey and more. As CFO, Yeh’s du­ties will cov­er cor­po­rate fi­nan­cial strate­gies, fi­nan­cial re­port­ing, risk man­age­ment, fund­ing, and IPO. Giv­en CStone’s am­bi­tious plan to go af­ter fron­trun­ners in the PD-L1 field (like Bris­tol-My­ers Squibb’s Yer­voyMer­ck’s Keytru­da and No­var­tis’ Mekin­ist) with its own Phase I drug can­di­date, Yeh is ex­pect­ed to con­tribute in­sight gleaned from his years lead­ing re­search on both Chi­nese and US biotech in­dus­tries. The im­muno-on­col­o­gy play­er has inked a cou­ple of li­cens­ing pacts with US biotechs, in­clud­ing with Agios on ivosi­denib, its new­ly ap­proved treat­ment for ad­vanced acute myeloid leukemia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.